News

BIO-CAT Partners with Kerry for Global Distribution of OPTI-BIOME MB40 Probiotic

BIO-CAT, Inc. has formed a global partnership with Kerry, the Taste & Nutrition company and their BIO-CAT Microbials, LLC probiotic products division. Effective June 2021, Kerry will lead the sales, marketing, and distribution of BIO-CAT’s proprietary probiotic strain, OPTI-BIOME MB40®.

OPTI-BIOME MB40® (Bacillus subtilis ATCC122264) is a non-GMO, highly-stable probiotic strain that the company says is an ideal ingredient for a wide array of dietary supplements and other related uses. A 2019 peer-reviewed study demonstrated promising results for the probiotic strain to support gastrointestinal health.

Kerry has extensive success marketing probiotics — the Ireland-based company has placed its GanedenBC30® (Bacillus coagulans GBI-30, 6086) probiotic in well over 1,000 food and beverage products around the world. BIO-CAT CEO Chris Schuler said he envisions similar success with MB40® in the dietary supplement space.

“Given the impressive performance of the MB40® strain and its potential to have a significant impact on the dietary supplement, functional food and beverage, and companion animal industries, we have decided to work with a partner who will help scale MB40® globally,” Schuler said. “Kerry’s expertise, commitment to develop a leading probiotic platform, access to global resources, and plans to further scientifically support MB40® make them an ideal partner.”

As part of the agreement, Kerry will apply its brand development capabilities to refresh the MB40® brand over the course of the coming months. Once fully developed, the new brand name will be supported by Kerry’s global marketing and commercial infrastructure — the company currently boasts a network of nearly 150 locations across 31 countries. According to John Quilter, VP & General Manager of Kerry’s ProActive Health business, “We are delighted to partner with Bio-Cat to further develop and market this unique and highly-stable Bacillus strain, which will complement our growing portfolio of science-backed branded ingredients in our ProActive Health portfolio.”

Recent News

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that